Table 1. Inhibitor compounds.

Inhibitor Name	Commercial name(s)	Company	FDA	IC50	Clinical Trial	Cancer Type	Reference
GDC-0449	Vismodegib/ Erivedge	Roche/Genentech/Curis	approved	0.5 uM DAOY cells	Phase 0, I, II, IV	BCC Medulloblastoma Prostate Esophageal Gastric Myeloid Leukemia Pancreatic Lung	72–76
IPI-926	Saridegib/Sadegib	Infinity Pharmaceuticals/Novartis	unnaproved	9 nM in C3H10T1/2 cells	Phase I, II	Mielofibrosis Chondrosarcoma Esophageal	77–78
BMS-833923/XL139	-	Exelixis/Bristol-Myers Squibb	unnaproved	10 um OE19 and OE33 cell lines	Phase I, II	Gastrointestinal Multiple myeloma Lung Gastrointestinal Multiple myeloma Solid tumours Myeloid leukaemia	79–80
LDE225	Erismodegib/Sonidegib/Odomzo	Novartis	approved	12 um A2780ip2 cell line	Phase I, II, III	Esophageal Ovarian Hepatocelular Prostate	81–83
AZD8542	-	AstraZeneca	approved	2.9 nM C3H10T1/2 cell line	Phase II	Pancreatic	84
SANT	-	SIGMA	unnaproved	20 nM in NIH 3T3 cell line	-	Basal cell Pancreatic Prostate Lung	85
GANT58	-	SIGMA	unnaproved	5 uM in NIH 3T3 cell line	-	Prostate Pancreatic Lung Glioma	86
GANT61	-	SIGMA	unnaproved	5uM in NIH 3T3 cell line	-	Prostate Pancreatic Lung Glioma	87